{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:27:49Z","timestamp":1793730469678,"version":"4.6.1"},"reference-count":40,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is associated with obesity. These analyses evaluated weight change with atogepant used as a preventive migraine treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Five atogepant clinical trials in adults with migraine (one phase 2b\/3; four phase 3) were included: Three 12-week, randomized, placebo-controlled trials (episodic migraine: two; chronic migraine: one); one 40-week, open-label extension trial and one 52-week, standard care, randomized, long-term safety trial in episodic migraine. Change from baseline in body weight was measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean baseline body mass indexes were 30.0\u201330.7\u2005kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (pooled episodic migraine [United States only]) and 25.0\u201325.5\u2005kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (chronic migraine [East Asia, Europe, and North America]). More participants treated with atogepant 60\u2005mg once-daily compared to placebo experienced \u22657% weight loss at any time in the pooled episodic migraine placebo-controlled trials (4.9% vs. 2.8%), chronic migraine placebo-controlled trial (5.8% vs. 2.0%), and pooled open-label extension and long-term safety trials (24.0% vs.14.7% in standard care [long-term safety only]). In the placebo-controlled trials, weight loss with atogepant 60\u2005mg once-daily was observed at week 2 (pooled episodic migraine: \u22120.32%; chronic migraine: \u22120.39%), increasing at week 12 (pooled episodic migraine: \u22121.02%; chronic migraine: \u22121.50%); compared to weight gain with placebo at week 12 (pooled episodic migraine: +0.49%; chronic migraine: +0.10%). In the long-term episodic migraine studies, weight loss with atogepant 60\u2005mg once-daily was observed at week 4 (long-term safety: \u22120.42%; open-label extension: \u22120.76%), increasing at week 40 (long-term safety: \u22122.38%; open-label extension: \u22122.09%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Atogepant was associated with modest dose- and duration-dependent weight loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifiers: NCT02848326 (CGP-MD-01); NCT03777059 (3101-301-002); NCT03700320 (long-term safety trial); NCT03939312 (open-label extension trial); NCT03855137 (3101-303-002).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024241299753","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T02:18:01Z","timestamp":1733710681000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis"],"prefix":"10.1177","volume":"44","author":[{"given":"B. Lee","family":"Peterlin","sequence":"first","affiliation":[{"name":"Pennsylvania Headache Center, Camp Hill, PA, USA"},{"name":"Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale S.","family":"Bond","sequence":"additional","affiliation":[{"name":"Hartford Hospital\/HealthCare, Hartford, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[{"name":"Georgetown University Hospital, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Phoenix, AZ, USA"},{"name":"Atria Academy of Science and Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"De Abreu Ferreira","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Smith","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3048-2633","authenticated-orcid":false,"given":"Brett","family":"Dabruzzo","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3260-5904","authenticated-orcid":false,"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[{"name":"NIHR King's Clinical Research Facility, King's College London, London, UK"},{"name":"Department of Neurology, University of California, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Trugman","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,8]]},"reference":[{"key":"bibr1-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"bibr2-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411398400"},{"key":"bibr3-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"bibr4-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a824f7"},{"key":"bibr5-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01459.x"},{"key":"bibr6-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003919"},{"key":"bibr7-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1111\/head.14356"},{"key":"bibr8-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22069"},{"key":"bibr9-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318212ab1e"},{"key":"bibr10-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7172"},{"key":"bibr11-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306883"},{"key":"bibr12-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01554.x"},{"key":"bibr13-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00059.2021"},{"key":"bibr14-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1358\/dnp.2010.23.2.1475909"},{"key":"bibr15-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-018-1202-3"},{"key":"bibr16-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1210\/en.2010-0284"},{"key":"bibr17-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.010629"},{"key":"bibr18-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30234-9"},{"key":"bibr19-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035908"},{"key":"bibr20-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1111\/head.14439"},{"key":"bibr21-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221128250"},{"key":"bibr22-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01049-8"},{"key":"bibr23-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr24-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437739.71477.ee"},{"key":"bibr25-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21358"},{"key":"bibr26-03331024241299753","first-page":"51S","volume":"6","author":"National Institutes of Health.","year":"1998","journal-title":"Obes Res"},{"key":"bibr27-03331024241299753","first-page":"11","volume":"64","author":"Hay D","year":"2024","journal-title":"Headache"},{"key":"bibr28-03331024241299753","first-page":"11","volume":"64","author":"Hay D","year":"2024","journal-title":"Headache"},{"key":"bibr29-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2021.147629"},{"key":"bibr30-03331024241299753","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S171365"},{"key":"bibr31-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c5222"},{"key":"bibr32-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001456"},{"key":"bibr33-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01456-2"},{"key":"bibr34-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-1609-7"},{"key":"bibr35-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01498-6"},{"key":"bibr36-03331024241299753","volume-title":"Topamax [package insert]","year":"2021"},{"key":"bibr37-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2007.00389.x"},{"key":"bibr38-03331024241299753","author":"Linde M","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr39-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2006.84"},{"key":"bibr40-03331024241299753","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-020-04429-z"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024241299753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024241299753","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024241299753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:09Z","timestamp":1777387569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024241299753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1177\/03331024241299753"],"URL":"https:\/\/doi.org\/10.1177\/03331024241299753","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"article-number":"03331024241299753"}}